Aim Immunotech Inc. ( (AIM) ) has released its Q2 earnings. Here is a breakdown of the information Aim Immunotech Inc. presented to its investors.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
AIM ImmunoTech Inc. is a biotechnology company specializing in the development of immunotherapeutic treatments for cancer, viral diseases, and immune-deficiency disorders, with its main products being Ampligen and Alferon N Injection. In its latest earnings report for the quarter ending June 30, 2025, AIM ImmunoTech Inc. reported a decrease in total revenues to $25,000 from $50,000 in the same quarter last year, alongside a net loss of $2.8 million, which is an increase from the $1.8 million loss reported in the previous year. The company continues to focus on its strategic initiatives, including clinical trials for Ampligen in treating pancreatic cancer and exploring its antiviral properties. Despite the financial challenges, AIM ImmunoTech remains committed to advancing its research and development efforts, with management expressing optimism about future clinical trials and potential regulatory approvals.